SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia
- Determine the potential of lestaurtinib with or without chemotherapy agents in treating
samples from infants with leukemia.
- Determine whether FLT3 protein expression level and/or activation and sensitivity to
lestaurtinib differ between subgroups of infants with leukemia.
- Determine whether lestaurtinib activates STAT5, AKT, and RAS-MAPK and other pathways.
- Determine whether lestaurtinib can synergize with other chemotherapy agents kill infant
OUTLINE: This is a multicenter study.
Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy
agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to
lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK
and other pathways by western blot. The most effective treatment from this study is then
validated in vivo in a NOD/SCID xenograft model.
Activity of lestaurtinib with and without chemotherapeutic agents
Patrick A. Brown, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government